arrow
M

Myung-Ju Ahn

Sungkyunkwan University School of Medicine
H指数:24
被引数:2,221

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial
2025-12-010
PRE
Phase II study of lazertinib and pemetrexed in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and leptomeningeal metastases: The KCSG LU 21-01, LAZARUS study

拉泽替尼联合培美曲塞治疗表皮生长因子受体突变阳性非小细胞肺癌合并软脑膜转移的II期研究:KCSG LU 21-01、LAZARUS研究

2025-11-010
PRE
Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real–world study

不可切除的III期EGFR突变非小细胞肺癌患者接受放化疗的突变检测、治疗模式与结局:一项全球真实世界研究的最终分析

2025-09-080
PREAI
Final analysis results and patient-reported outcomes from DESTINY-Lung02—a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small cell lung cancer

最终分析结果和患者报告结局来自DESTINY-Lung02——一项关于曲妥珠单抗德鲁替康在HER2突变型转移性非小细胞肺癌患者中的剂量盲法、随机、II期研究

2025-07-300
PREAI
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status

克唑替尼耐药的ALK阳性非小细胞肺癌患者中,brigatinib的活性根据ALK融合和突变状态。

2025-06-060
OAAI
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC—A Brief Report

更新了来自II期PHAROS研究的encorafenib联合binimetinib在BRAF V600E突变型转移性NSCLC患者中的疗效和安全性——简报

2025-06-040
OAAI
EGFR mutation testing across the osimertinib clinical program

奥希替尼临床项目中的EGFR突变检测

2025-06-010
PRE
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK plus NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials

布加替尼在ALK TKI初治的ALK阳性晚期NSCLC患者中的疗效和安全性:ALTA-1L和J-ALTA试验的整合分析

2025-03-010
PRE
Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study

奥希替尼在参加AURA计划或FLAURA研究的EGFRm NSCLC患者中的长期耐受性

2025-01-010
PRE